A recent study shows that Bristol Myers Squibb’s oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was associated with noticeable improvements in signs and symptoms of psoriatic arthritis compared with placebo.
Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.
Additional findings from Biogen’s Phase II LILAC study show the biotech company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus (SLE).
Regeneron Pharmaceuticals Inc.’s coronavirus antibody cocktail – the experimental treatment that U.S. President Donald Trump received – significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate Covid-19.
Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).
Johnson & Johnson announced a major milestone as the company launched a large-scale, international Phase III trial for the Covid-19 vaccine candidate JNJ-78436735.
San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.
Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.
Pfizer Inc. said participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
The National Institutes of Health launched two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating Covid-19 among adults.
